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OBJECTIVES: HIV-related renal diseases are the leading causes of chronic kidney diseases worldwide. The
present study aimed to investigate the prevalence of pathological proteinuria and its risk factors among HIV
patients.
METHODS: A review of the medical records of 666 HIV-infected individuals aged 18 years or older in an urban HIV/
AIDS clinic based in Porto Alegre in southern Brazil. Overt proteinuria was defined as a protein-to-creatinine ratio
greater than 150 mg/g according to Kidney Disease: Improving Global Outcomes.
RESULTS: The prevalence of pathological proteinuria in the present study cohort was 20%. Characteristics
associated with pathological proteinuria after univariate analysis included alcohol abuse, hepatitis C virus
coinfection, the occurrence of diabetes and therapy including tenofovir. Adjusted residuals analysis indicated an
association between pathological proteinuria and both a CD4 lymphocyte count below 200 cells/mm3 and a viral
load higher than 1000 copies/mL. Additionally, an absence of pathological proteinuria was associated with
a CD4 lymphocyte count higher than 500 cells/mm3. After adjustment for variables with po0.2 in the univariate
analysis using a Poisson regression model, tenofovir-containing regimens and a CD4 lymphocyte count
below 200 cells/mm3 were significantly associated with pathological proteinuria.
CONCLUSION: The risk of chronic kidney diseases in this large contemporary cohort of HIV-infected individuals
appeared to be attributable to a combination of HIV-related risk factors. In addition to the traditional risk
factors cited in the literature, both regimens containing tenofovir and HIV disease severity seem to be
associated with chronic kidney diseases in patients with HIV. Assessment of proteinuria constitutes a novel
method for chronic kidney disease staging in HIV-infected individuals and may be effectively used to stratify the
risk of progression to end-stage renal disease.
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’ INTRODUCTION
HIV-related renal diseases are one of the leading causes of
chronic kidney diseases (CKDs) worldwide. In particular, the
new era of highly active antiretroviral therapy (HAART) and
early HIV diagnosis has improved survival and disease
progression, leading to a higher proportion of patients with
renal abnormalities over time (1-3).
CKD is defined by a sustained change in urinary sediment,
such as the presence of proteinuria, or by a reduced glomerular
filtration rate (GFR). Proteinuria is often the earliest manifestation
of CKD and is more common in HIV-infected individuals than in
similarly aged HIV-negative controls (1,4,5). Risk factors for
incident or progressive CKD in HIV-positive adults include
apolipoprotein-1 genetic polymorphism (4), hepatitis C virus
(HCV) coinfection (5), a low CD4 T-cell count, a high HIV viral
load and traditional CKD risk factors such as diabetes and
hypertension (6).
The present study aimed to investigate the prevalence of
pathological proteinuria and its risk factors among HIV patients
from a public HIV/AIDS reference clinic in Porto Alegre, Brazil.
’ MATERIALS AND METHODS
The present research was a cross-sectional study of HIV-
infected patients who attended a public HIV/AIDS clinic in
Porto Alegre, Brazil. The data were collected from the
records of patients who attended between March 2008 and
December 2012. The study population included HIV patients
aged 18 years or older who were from the city of PortoDOI: 10.6061/clinics/2015(10)06
Copyright & 2015 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
691
CLINICAL SCIENCE
Alegre and surrounding metropolitan region. All partici-
pants had free access to health care and medications, in line
with the national health program. Cases were excluded if
records were not available for analysis.
Data collected from records included age, gender, ethnicity,
body mass index (BMI), smoking history, use of illicit drugs
and alcohol, previous diagnosis of hypertension, diabetes
mellitus, chronic hepatitis B infection, chronic HCV infection,
lipid levels, glucose levels, urinalysis results, arterial hyperten-
sion, drugs being used, current CD4 count (cells/mm3), current
plasma HIV RNA level (viral load), absence (naı¨ve) or use of
HAART and type of HAART under use.
Urine samples were analyzed by the Department of
Laboratory Medicine at the Universidade Federal do Rio
Grande do Sul, Porto Alegre, Brazil and the diagnosis of
proteinuria was made based on the urinary protein-to-creatinine
ratio (PCR) in a single-spot urine analysis (3). Overt proteinuria
was defined as a PCR greater than 150 mg/g according to
Kidney Disease: Improving Global Outcomes (KDIGO) (7).
Blood pressure was determined based on an average of
two measurements using a calibrated automated machine,
with each participant sitting in a relaxed, upright position.
Hypertension was defined according to standard definitions
set out in the Eighth Joint National Committee guidelines (8).
Patients receiving an antihypertensive medication, irrespec-
tive of blood pressure, were also defined as hypertensive (8).
The criteria for the definitions of diabetes and dyslipidemia
followed ADA (9) and AACE (10) guidelines.
Statistical analyses included descriptive statistics with
numbers (proportions) for categorical variables and means
(± standard deviation) for continuous variables. Categorical
variables were assessed using the chi-square test or Fisher’s
exact test and quantitative variables were compared using
Student’s t-test. Adjusted residual analysis was performed to
detect categories with a two-tailed (higher or lower) expected
frequency.
Significant variables with po0.20 in the univariate
analysis were further analyzed using a Poisson regression
model with robust variance. Fosamprenavir plus ritonavir
(FPV/r) treatment was not included in this model due to its
use by only a small number of patients. A value of po0.05
was considered statistically significant. All statistical ana-
lyses were performed using the SPSS software, version 18
(IBM, Armonk, NY, USA).
Ethics
The present research was approved by the Ethics
Committee of the Municipal Council of Health of Porto
Alegre city, under protocol number 05773912.1.0000.5338, in
January 2013.
’ RESULTS
Demographics
Initially, 744 HIV-infected individuals were identified, but
78 were excluded due to a lack of complete medical records.
Therefore, the medical records of 666 HIV-infected indivi-
duals aged 18 years or older in an urban HIV/AIDS clinic
based in Porto Alegre in southern Brazil were ultimately
evaluated. The mean age of the group was 42.02±11.8 years
and 51.5% were male. Moreover, 60.7% of the individuals
were Caucasian and 39.3% were Black. Diabetes mellitus
was present in only 5.9% of the study population, whereas
dyslipidemia was present in 26.2%. A smoking habit was
present in 39.3%, and 13.7% of evaluated patients had a BMI
higher than 30 kg/m2. In terms of the CD4 count, 10.5% had
a current count o200 cells/mm3; 42.4%, between 200 and
500 cells/mm3; and 47.1%, 4500 cells/mm3. In total, 60%
had an undetectable viral load (o50 copies/mL) and
77.7% were currently receiving HAART. Finally, only two
patients had serum creatinine greater than 1.5 mg/dL.
The group demographic values are presented in Table 1.
The prevalence of hypertension in this study cohort was
22.5% (227 individuals). A total of 150 patients were taking
antihypertensive drugs. More specifically, 77 individuals
(51.33%) were taking only one antihypertensive, 50 (33.33%)
were taking two and 23 (15.33%) were taking a combination
of three or more drugs. The most common antihypertensive
medications were angiotensin-converting enzyme inhibitors
(n=100), diuretics (n=61), beta-blockers (n=47), angiotensin
II receptor antagonists (n=20) and calcium channel blockers
(n=12). In contrast, in the studied group, 61 (40.66%)
individuals did not have controlled blood pressure, despite
antihypertensive therapy.
Characteristics associated with
pathological proteinuria
The prevalence of pathological proteinuria in the present
study cohort was 20% (95% CI: 16.9% to 23.0%), with no
difference observed between the groups receiving HAART
(19.2%) and not receiving HAART (20.7%) (p=0.773). The
mean ages of the individuals in the pathological proteinuria
group and the non-pathological proteinuria group were
45.8±12.7 years and 41.1±11.4 years, respectively (p=0.003).
Characteristics associated with pathological proteinuria after
univariate analysis included alcohol abuse (p=0.019), HCV
coinfection (po0.001) and the occurrence of diabetes
(p=0.006). Therapy including tenofovir among individuals
under HAART presented a similar association (po0.001).
Adjusted residuals analysis indicated an association between
pathological proteinuria and both a CD4 lymphocyte count
below 200 cells/mm3 (po0.001) and viral load higher than
1000 copies/mL (p=0.026). Additionally, an absence of patho-
logical proteinuria was associated with a CD4 lymphocyte
count higher than 500 cells/mm3 (po0.001).
When the individuals under tenofovir therapy were
evaluated regarding proteinuria, 30.11% (53/176) patients
had pathological proteinuria and only 20.75% (11/53) of
these individuals had albuminuria detected by dipstick.
After adjustment for all variables with po0.2 in the
univariate analysis using a Poisson regression model,
tenofovir-containing regimens and a CD4 lymphocyte count
below 200 cells/mm3 were significantly associated with
pathological proteinuria. Additionally, within this setting,
a viral load higher than 1,000 copies/mL (p=0.065) showed
a tendency toward association with pathological proteinuria.
The regression model values are shown in Table 2.
’ DISCUSSION
Proteinuria is part of the definition of CKD and is a risk
marker for progression to end-stage renal disease (ESRD).
HIV-associated nephropathy (HIVAN)-related risk factors,
including an elevated HIV RNA level, a low absolute
CD4 lymphocyte count, apolipoprotein-1 genetic polymor-
phism and hepatitis C and hepatitis B coinfection, are
associated with proteinuria (2). The present study detected
a high prevalence of pathological proteinuria (20%) among
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HIV-infected individuals, similar to other studies in the
literature, which have reported prevalence values ranging
from 17% to 32% (1,11).
This study examined the factors associated with proteinuria
within a large cohort of HIV-infected patients. Proteinuria was
specifically associated with an elevated HIV RNA level and a
CD4 lymphocyte count below 200 cells/mm3. These findings
are consistent with prior studies, in which risk factors for
incident or progressive CKD in HIV-positive adults included
HIV disease severity (1,7,11-13). However, factors tradition-
ally associated with CKD that have been described in the
literature, such as age, cardiovascular disease (1,4), diabetes,
hypertension, obesity (6,12) and HCV (13), were not linked to
pathological proteinuria among HIV-positive individuals in
the current study after multivariate analysis.
The relationship between antiretrovirals and pathological
proteinuria was also examined and tenofovir-based therapy
was significantly associated with this condition in the
multivariate analysis. Most of the individuals in this group
who presented with pathological proteinuria did not have
albuminuria detected by dipstick (79.25%), suggesting
proteinuria of tubular origin. Thus, these patients would
not have benefited from using angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers. Mean-
while, FPV/r therapy showed a tendency toward association
with pathological proteinuria. However, due to the small
number of patients, fosamprenavir was not included in the
multivariate analysis. All other antiretrovirals were not
linked to pathological proteinuria.
Patients with HIV infection are at risk of developing
nephrotoxicity in response to antiretrovirals. In fact, tenofo-
vir and boosted protease inhibitors have been associated
with a decline in the GFR (14,15). Tenofovir is specifically a
nucleoside reverse transcriptase inhibitor that can cause
acute kidney injury (AKI), proximal tubular dysfunction, or
both in combination. The risk of kidney toxicity with
tenofovir has varied across different studies, with estimates
ranging from 2% to 10% (15,16).
Table 1 - Demographic data comparing groups of pathological proteinuria and non-pathological proteinuria individuals.
Factors N Total (%) Pathological
Proteinuria Group
Non-Pathological
Proteinuria Group
p value
Population size 666 (100%) 133 (20.0) 533 (80.0) -
Age, years 666 0.003
18-39 288 (43.2) 42 (31.6) 246 (46.2)
4 40 378 (56.0) 91 (68.4) 287 (53.8)
Gender, male 666 343 (51.5) 62 (46.6) 281 (52.7) 0.245
Ethnicity 603
Caucasian 366 (60.7) 71 (57.7) 295 (61.5) 0.514
Abuse on drugs
Alcohol 635 92 (14.5) 26 (21.7) 66 (12.8) 0.019
Tabaco 634 249 (39.3) 54 (45.5) 195 (37.9) 0.159
Crack cocaine 635 24 (3.8) 6 (5.0) 18 (3.5) 0.431
Inhaled cocaine 634 21 (3.3) 2 (1.7) 19 (3.7) 0.396
Cannabis 634 19 (3.0) 4 (3.3) 15 (2.9) 0.769
Body mass index 408
Obese (X 30.0) 56 (13.7) 12 (15.2) 44 (13.4) 0.811
Diabetes mellitus 665 39 (5.9) 15 (11.3) 24 (4.5) 0.006
Dyslipidemia 665 174 (26.2) 35 (26.3) 139 (26.1) 1
Hypertension 659 142 (21.5) 36 (27.1) 106 (20.2) 0.106
Chronic hepatitis B 666 20 (3.0) 7 (5.3) 13 (2.4) 0.094
Chronic hepatitis C 664 80 (12.0) 29 (21.8) 51 (9.6) o 0.001
Current CD4 count, cells/mm3 665 0.001
X500 313 (47.1) 47 (35.3) 266 (50.0)
200-500 282 (42.4) 62 (46.6) 220 (41.4)
o 200 70 (10.5) 24 (18.0) 46 (8.6)
HIV RNA, copies/mL 666 0.026
o 50 398 (59.8) 76 (57.1) 322 (60.4)
50-1,000 110 (16.4) 15 (11.3) 95 (17.8)
41,000 158 (23.7) 42 (31.6) 116 (21.8)
HAART regimen 651
Yes 506 (77.7) 97 (76.4) 409 (78.1) 0.773
Current use of NRTI or NOT 637 o 0.001
TDF+3TC 175 (27.5) 52 (43.3) 123 (23.8)
AZT+3TC 317 (49.8) 38 (31.7) 279 (54)
NAIVE 145 (22.8) 30 (25) 115 (22.2)
Based-therapy 666
NNRTI
Efavirenz 197 (29.6) 37 (27.8) 160 (30.0) 0.696
Nevirapine 6 (0.9) 1 (0.8) 5 (0.9) 1
Protease inhibitors
Lopinavir 155 (23.3) 30 (22.6) 125 (23.5) 0.917
Atazanavir 126 (18.9) 27 (20.3) 99 (18.6) 0.741
Fosamprenavir 14 (2.1) 0 (0.0) 14 (2.6) 0.085
Darunavir 8 (1.2) 2 (1.5) 6 (1.1) 0.663
3TC: Lamivudine; AZT: Zidovudine; HAART: highly active antiretroviral therapy; NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: Non- nucleoside
reverse transcriptase inhibitors; TDF: Tenofovir.
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The benefits of antiretrovirals concerning proteinuria may
be less substantial with regimens containing tenofovir
compared with the alternative, namely, nucleoside reverse
transcriptase inhibitors (17). Although a kidney biopsy may
not be necessary to diagnose tenofovir toxicity, it can be
useful in cases where the diagnosis is less clear or where
there are compelling reasons not to discontinue tenofovir
(18). In addition, in the setting of renal disease, a regimen
containing a boosted protease inhibitor (such as FPV/r) in
combination with tenofovir has been associated with a
decrease in the GFR (14, 19).
The present study has certain limitations. For example,
several of our findings could have been underestimated,
given that the durations of HIV disease and HAART were
not evaluated. Additionally, our analyses were based on a
cross-sectional study; hence, the temporality between factors
and the development of pathological proteinuria could not
be established. It was also difficult to estimate the number of
patients with CKD due to the small proportion of patients
with abnormal serum creatinine.
Conversely, our study possessed certain strengths as well.
In particular, this study was conducted in a population of
HIV-infected persons with clinical follow-up and reliable
information concerning antiretroviral use. The group studied
was representative for two reasons: a large cohort of patients
was evaluated and the profile of the patients within the
group is similar to that of patients currently attending HIV
clinics.
In conclusion, the risk of CKD in this large contemporary
cohort of HIV-infected individuals appeared to be attribu-
table to a combination of HIV-related risk factors. In addition
to the traditional risk factors cited in the literature, both
regimens containing tenofovir and HIV disease severity
seem to be very important factors associated with CKD in
patients with HIV.
Assessment of proteinuria constitutes a novel method for
CKD staging in HIV-infected individuals and may be
effectively used to stratify the risk of progression to ESRD.
Given the increasing incidence of HIV-related renal diseases as
a cause of ESRD and the increased mortality risk that ESRD
imparts, further investigation of strategies to prevent or treat
the renal complications of HIV infection is imperative.
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